330986 RESULTS
COMMENT This study raises some intriguing possibilities. Loss of retromer expression has long been noted in AD, with consequent effects on APP processing and Aβ production. However, retromer recycling appears as a nexus for parkinsonism and dementia. Deficits in
COMMENT My reaction is that the new pro-retromer drug is brilliant and essential, and at the very least, we have a terrific new tool for cell biology at the bench. In contemplating its use in treating or preventing AD, there are some caveats that tend to keep me
COMMENT Scott Small, Dagmar Ringe, Greg Petsko, and their colleagues are to be congratulated on a beautiful piece of science. This paper represents the combination of expert structural biology and AD cell biology to produce simultaneous advances in both arenas. T
RESEARCH NEWS 2014-04-20 Research News A potential Alzheimer’s treatment aims to whisk the amyloid precursor protein (APP) out of harm’s way to prevent it from generating Aβ. The small molecule fortifies the retromer, a large protein conglomerate that ferries APP out of endosomes
United States
COMMENT We were happy to see that the authors were able to recapitulate formation of α-synuclein Lewy body and Lewy Neurite-like inclusions by intracranially injecting synthetic fibrils made from recombinant protein into the hippocampus and cortex of both non-tra
Thomas Jefferson University
Avondale, United States
University of PennsylvaniaPhiladelphia, United States
PAPER Paslawski W, Mysling S, Thomsen K, Jørgensen TJ, Otzen DE
PAPER Moriarty GM, Minetti CA, Remeta DP, Baum J
PAPER Okumiya K, Wada T, Fujisawa M, Ishine M, Garcia Del Saz E, Hirata Y, Kuzuhara S, Kokubo Y, Seguchi H, Sakamoto R, Manuaba I, Watofa P, Rantetampang AL, Matsubayashi K
PAPER Dib S, Xiao S, Miletic D, Robertson J
PAPER Perera ND, Sheean RK, Scott JW, Kemp BE, Horne MK, Turner BJ
PAPER Roh JH, Lee JH
No filters selected
